Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions

W. F. Keane, Sharon Anderson, M. Aurell, D. De Zeeuw, R. G. Narins, G. Povar

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

ACE inhibitors are tolerated by azotemic patients, although transient reductions in renal function can occur. Patients with bilateral renal insufficiency or low cardiac output are at increased risk for developing reversible acute renal insufficiency. Hyperkalemia may occur, particularly in patients with diabetes or severe renal insufficiency. In many patients with renal disease, ACE inhibitors dramatically reduce proteinuria, but whether they also reduce the rate of progression of renal disease remains unproved.

Original languageEnglish (US)
Pages (from-to)503-516
Number of pages14
JournalAnnals of Internal Medicine
Volume111
Issue number6
StatePublished - 1989
Externally publishedYes

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Renal Insufficiency
Kidney
Low Cardiac Output
Hyperkalemia
Proteinuria
Acute Kidney Injury
Disease Progression
Direction compound

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions. / Keane, W. F.; Anderson, Sharon; Aurell, M.; De Zeeuw, D.; Narins, R. G.; Povar, G.

In: Annals of Internal Medicine, Vol. 111, No. 6, 1989, p. 503-516.

Research output: Contribution to journalArticle

Keane, W. F. ; Anderson, Sharon ; Aurell, M. ; De Zeeuw, D. ; Narins, R. G. ; Povar, G. / Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions. In: Annals of Internal Medicine. 1989 ; Vol. 111, No. 6. pp. 503-516.
@article{cf22055c5274489d87d29586cd599634,
title = "Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions",
abstract = "ACE inhibitors are tolerated by azotemic patients, although transient reductions in renal function can occur. Patients with bilateral renal insufficiency or low cardiac output are at increased risk for developing reversible acute renal insufficiency. Hyperkalemia may occur, particularly in patients with diabetes or severe renal insufficiency. In many patients with renal disease, ACE inhibitors dramatically reduce proteinuria, but whether they also reduce the rate of progression of renal disease remains unproved.",
author = "Keane, {W. F.} and Sharon Anderson and M. Aurell and {De Zeeuw}, D. and Narins, {R. G.} and G. Povar",
year = "1989",
language = "English (US)",
volume = "111",
pages = "503--516",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "6",

}

TY - JOUR

T1 - Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions

AU - Keane, W. F.

AU - Anderson, Sharon

AU - Aurell, M.

AU - De Zeeuw, D.

AU - Narins, R. G.

AU - Povar, G.

PY - 1989

Y1 - 1989

N2 - ACE inhibitors are tolerated by azotemic patients, although transient reductions in renal function can occur. Patients with bilateral renal insufficiency or low cardiac output are at increased risk for developing reversible acute renal insufficiency. Hyperkalemia may occur, particularly in patients with diabetes or severe renal insufficiency. In many patients with renal disease, ACE inhibitors dramatically reduce proteinuria, but whether they also reduce the rate of progression of renal disease remains unproved.

AB - ACE inhibitors are tolerated by azotemic patients, although transient reductions in renal function can occur. Patients with bilateral renal insufficiency or low cardiac output are at increased risk for developing reversible acute renal insufficiency. Hyperkalemia may occur, particularly in patients with diabetes or severe renal insufficiency. In many patients with renal disease, ACE inhibitors dramatically reduce proteinuria, but whether they also reduce the rate of progression of renal disease remains unproved.

UR - http://www.scopus.com/inward/record.url?scp=0024440199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024440199&partnerID=8YFLogxK

M3 - Article

VL - 111

SP - 503

EP - 516

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 6

ER -